NASDAQ:TXMD - TherapeuticsMD Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $5.13 +0.09 (+1.79 %) (As of 01/16/2019 04:46 AM ET)Previous Close$5.04Today's Range$4.88 - $5.1752-Week Range$3.51 - $7.66Volume2.47 million shsAverage Volume3.22 million shsMarket Capitalization$1.23 billionP/E Ratio-13.86Dividend YieldN/ABeta1.54 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email TherapeuticsMD, Inc. operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen. The company also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaMedMD and BocaGreenMD brands. It markets its products primarily through a direct national sales force to health care providers in the OB/GYN market space. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida. Receive TXMD News and Ratings via Email Sign-up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TXMD Previous SymbolNYSEMKT:TXMD CUSIPN/A Webwww.therapeuticsmd.com Phone561-961-1900Debt Debt-to-Equity Ratio0.55 Current Ratio7.23 Quick Ratio7.15Price-To-Earnings Trailing P/E Ratio-13.86 Forward P/E Ratio-8.69 P/E GrowthN/A Sales & Book Value Annual Sales$16.78 million Price / Sales72.72 Cash FlowN/A Price / Cash FlowN/A Book Value$0.60 per share Price / Book8.55Profitability EPS (Most Recent Fiscal Year)($0.37) Net Income$-76,920,000.00 Net Margins-757.59% Return on Equity-102.15% Return on Assets-67.96%Miscellaneous Employees173 Outstanding Shares237,880,000Market Cap$1.23 billion OptionableOptionable TherapeuticsMD (NASDAQ:TXMD) Frequently Asked Questions What is TherapeuticsMD's stock symbol? TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD." How were TherapeuticsMD's earnings last quarter? TherapeuticsMD Inc (NASDAQ:TXMD) released its quarterly earnings data on Wednesday, November, 7th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.06. The business earned $3.47 million during the quarter, compared to analyst estimates of $4.43 million. TherapeuticsMD had a negative return on equity of 102.15% and a negative net margin of 757.59%. The company's revenue was down 21.5% compared to the same quarter last year. During the same period last year, the company posted ($0.07) EPS. View TherapeuticsMD's Earnings History. When is TherapeuticsMD's next earnings date? TherapeuticsMD is scheduled to release their next quarterly earnings announcement on Tuesday, February 19th 2019. View Earnings Estimates for TherapeuticsMD. What price target have analysts set for TXMD? 4 equities research analysts have issued 12 month price objectives for TherapeuticsMD's shares. Their forecasts range from $11.00 to $27.00. On average, they expect TherapeuticsMD's stock price to reach $17.3333 in the next year. This suggests a possible upside of 237.9% from the stock's current price. View Analyst Price Targets for TherapeuticsMD. What is the consensus analysts' recommendation for TherapeuticsMD? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TherapeuticsMD. Has TherapeuticsMD been receiving favorable news coverage? News coverage about TXMD stock has been trending negative this week, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. TherapeuticsMD earned a media sentiment score of -2.5 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an effect on the company's share price in the near term. Are investors shorting TherapeuticsMD? TherapeuticsMD saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 70,149,536 shares, an increase of 0.9% from the December 14th total of 70,801,039 shares. Based on an average daily trading volume, of 4,302,831 shares, the days-to-cover ratio is currently 16.3 days. Currently, 35.9% of the company's shares are sold short. View TherapeuticsMD's Current Options Chain. Who are some of TherapeuticsMD's key competitors? Some companies that are related to TherapeuticsMD include TESARO (TSRO), FibroGen (FGEN), Amneal Pharmaceuticals (AMRX), GW Pharmaceuticals PLC- (GWPH), Array Biopharma (ARRY), Taro Pharmaceutical Industries (TARO), Horizon Pharma (HZNP), Evotec (EVTCY), Emergent Biosolutions (EBS), Intercept Pharmaceuticals (ICPT), Agios Pharmaceuticals (AGIO), Ascendis Pharma A/S (ASND), HUTCHISON CHINA/S (HCM), Ligand Pharmaceuticals (LGND) and Akcea Therapeutics (AKCA). Who are TherapeuticsMD's key executives? TherapeuticsMD's management team includes the folowing people: Mr. Robert G. Finizio, Co-Founder, CEO & Director (Age 47)Mr. John C. K. Milligan IV, Pres, Sec. & Director (Age 56)Dr. Brian A. Bernick, Co-Founder, Chief Clinical Officer & Director (Age 50)Mr. Daniel Alan Cartwright, CFO & Treasurer (Age 60)Mr. Mitchell L. Krassan, Exec. VP & Chief Strategy Officer (Age 52) Who are TherapeuticsMD's major shareholders? TherapeuticsMD's stock is owned by a number of of retail and institutional investors. Top institutional investors include Sanders Morris Harris LLC (0.18%). Company insiders that own TherapeuticsMD stock include Brian Bernick, Daniel A Cartwright, John CK Iv Milligan, Robert G Finizio and Tommy G Thompson. View Institutional Ownership Trends for TherapeuticsMD. Which institutional investors are buying TherapeuticsMD stock? TXMD stock was acquired by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC. View Insider Buying and Selling for TherapeuticsMD. How do I buy shares of TherapeuticsMD? Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is TherapeuticsMD's stock price today? One share of TXMD stock can currently be purchased for approximately $5.13. How big of a company is TherapeuticsMD? TherapeuticsMD has a market capitalization of $1.23 billion and generates $16.78 million in revenue each year. The company earns $-76,920,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. TherapeuticsMD employs 173 workers across the globe. What is TherapeuticsMD's official website? The official website for TherapeuticsMD is http://www.therapeuticsmd.com. How can I contact TherapeuticsMD? TherapeuticsMD's mailing address is 6800 BROKEN SOUND PARKWAY NW, BOCA RATON FL, 33487. The company can be reached via phone at 561-961-1900 or via email at [email protected] MarketBeat Community Rating for TherapeuticsMD (NASDAQ TXMD)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 260 (Vote Outperform)Underperform Votes: 209 (Vote Underperform)Total Votes: 469MarketBeat's community ratings are surveys of what our community members think about TherapeuticsMD and other stocks. Vote "Outperform" if you believe TXMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TXMD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/16/2019 by MarketBeat.com StaffFeatured Article: How are institutional investors different from individual investors?